JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK [1]. As the same as ALK inhibitor 1, ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase as well.In vitro: ALK inhibitor 2 (2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino] pyrimidin-4-yl]amino]-N-methylbenzenesulfonamide) is a chemical analogue of LDK378 that is a potent ALK inhibitor [2]. In vivo: No animal in-vivo data available currently. Clinical trial: Currently ALK inhibitor 2 is only in the preclinical developlent stage and no clinical data are available.Reference:[1] Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420(3):345-61. [2] Marsilje TH, Pei W, Chen B, Lu W, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56(14):5675-90.